Salvador Payán Pernía Highlights PIGA Gene Case and Thalassemia Advances at 5th Rare Diseases Conference in Hematology
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn:
”Yesterday, the 5th Rare Diseases Conference in Hematology took place, organized by our colleagues at the Regional Hospital of Malaga.
Our case, that of a family with a germline mutation in the PIGA gene, which is associated with a phenotype of epilepsy, mental retardation, and juvenile hereditary hemochromatosis, was chosen for oral presentation, which was superbly delivered by our resident Manuel Vázquez and Alexandra Elbers, a resident at Basurto Hospital who has chosen us for her external rotation in Erythropathology.
This gene is best known for the relationship between somatic mutations and paroxysmal nocturnal hemoglobinuria (PNH).
In turn, I spoke about the “treatment of intermediate thalassemia in 2026.”
A few hours earlier, the EMA approved mitapivat, based on a clinical trial in which we participated at the Virgen del Rocío University Hospital.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show